Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer

Swathi Mohankumar and Tushar Patel

Corresponding author: Tushar Patel, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32224. Tel.: 904 956 3257; Fax: 904 956 3359; E-mail: patel.tushar@mayo.edu

Abstract

Analysis of extracellular vesicles (EV) and their contents may be useful as disease biomarkers if they reflect the contents of cells of origin, differ between normal and diseased tissue and can be reliably detected. An increasing number of long non-coding RNA (lncRNA) are being reported to be aberrantly expressed in human cancers. These tumor-associated lncRNA may have potential as new biomarkers of disease. In this review, we highlight lncRNAs that are commonly associated with hepatocellular cancer, and summarize their potential biological roles and underlying molecular mechanisms. While lncRNA can be detected in the circulation, their low expression within circulating vesicles will require the use of highly sensitive detection technologies such as digital polymerase chain reaction or next-generation sequencing. While the integrity and functional role of tumor-specific lncRNAs within EV have yet to be established, their presence or enrichment within tumor cell-derived EV offers promise for their potential as disease biomarkers.

Key words: hepatocellular cancer; exosomes; extracellular vesicles; RNA genes; cancer diagnosis; digital PCR

Introduction

Extracellular vesicles (EVs) are small membrane-bound vesicles that are released into the interstitial fluid from a wide variety of normal or diseased cells. The predominant types of EVs are exosomes, microvesicles and apoptotic bodies and these are distinguished on the basis of their size and biogenesis [1]. Exosomes have a diameter of 30–100 nm and are cell-derived vesicles that are thought to be released from intracellular multivesicular bodies. In contrast, microvesicles and microparticles range in size from 100 to 1000 nm, are released from the plasma membrane during cell stress via exocytic budding. Apoptotic bodies are larger, with a diameter of >1000 nm and are released from cells undergoing apoptosis (Figure 1). These vesicles contain a variety of proteins, lipids, RNA and DNA molecules [2]. Some of these may be selectively enriched within EVs during their formation. Recent studies have highlighted a key role of EVs in intercellular communication through the transfer of their contents such as RNA that can functionally modulate cellular activities in recipient cells [3]. The RNA content of EVs include messenger RNA (mRNA), microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) [2]. Different types of EVs have been detected in many different body fluids. Consequently, they may potentially contribute to distant communication, an intriguing proposition that warrants systematic study.

EVs can be detected and isolated from body fluids. Analysis of EVs and their contents may have additional utility as disease biomarkers if they reflect the contents of cells of origin, differ between normal and diseased tissue and can be reliably detected. LncRNAs are a group of noncoding RNAs with diverse functions that are becoming increasingly recognized. In this overview we will focus on the lncRNA content of EVs, and their potential application and utility as disease biomarkers, using hepatocellular cancer (HCC) as an example. HCC-derived EVs have been shown to have selective enrichment of lncRNA, and some of these such as...
TUC339, linc-RNA ROR and lincRNA-VLDLR have been implicated in tumor cell behavior [4]. Enrichment of some lncRNA within circulating EVs may offer protection from degradation. Although EV transfer of lncRNA may have pathophysiological relevance, the precise function of many lncRNA is not known. Moreover, the functional integrity and capability of lncRNA within EV remains to be established. However, these limitations in our understanding of the functional or pathophysiological role of EV lncRNA do not impact on their potential utility as disease biomarkers [5].

**The need for new biomarkers for liver cancer**

HCC is the most common type of primary liver cancer in adults and is a leading cause of cancer-related deaths worldwide, resulting in close to 750,000 deaths worldwide every year [6, 7]. Within the United States, the prevalence of HCC has been increasing by 1.75% per year, which is a cause for concern [8]. The major established risk factors for HCC are cirrhosis, viral hepatitis B or C infection and nonalcoholic fatty liver disease. Conditions associated with chronic liver injury caused by diseases such as alcoholic liver disease, hemochromatosis, primary biliary cirrhosis and toxins such as aflatoxins are additional risk factors for HCC [6]. The majority of HCC are diagnosed at an advanced stage after clinical deterioration has occurred and when curative therapy is not possible. HCC is associated with poor survival. Although advanced cancers have a poor survival, with a 5-year survival rate of <10% from the time of diagnosis, the survival in patients with resectable early-stage disease is much higher with a 5-year survival rate approaching 70% [6]. Surgical resection has been shown to be most beneficial for tumors that are still small singular nodules <2 cm wide [9]. Early detection of HCC at a time when surgery for cure can be performed offers the best option to improve outcomes from HCC. Indeed, screening and surveillance for HCC in patients with HBV and cirrhosis have reduced mortality from HCC. Thus, surveillance strategies to identify early HCC in persons at risk is justified and warranted.

Diagnostic tools for the detection of early HCC include serum biomarkers, radiological imaging such as abdominal ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) and liver biopsy. Ultrasonography is frequently used for screening, but has poor sensitivity for detection of smaller tumors [9]. Widespread use of CT and MRI for screening is limited because of their cost or associated risks of radiation exposure [6]. The use of more specialized techniques such as angiography is not practical for screening and surveillance [10]. Liver biopsy is invasive, and the risk of needle tracking or extrahepatic spread makes it undesirable for use to diagnose smaller lesions that may be amenable to transplantation or surgical resection with curative intent.

Analysis of serum tumor markers is an attractive choice for screening for HCC. The most common marker used to detect HCC is alpha fetoprotein (AFP). Serum AFP levels are elevated in some, but not all persons with HCC, and AFP levels >400 ng/ml are highly correlated with HCC [6]. However, AFP lacks the sensitivity necessary for accurate diagnosis and often misses small early-stage tumors. Furthermore, serum AFP levels can be elevated in patients with ongoing regeneration associated with hepatic injury in the absence of malignancy [7]. Although several other markers e.g. serum des-gamma carboxyprothrombin have been evaluated for HCC, they have not proven to be of greater utility, and thus, existing serum biomarkers lack adequate sensitivity and specificity for early detection of HCC. [6]. Therefore, a clear need exists for more effective biomarkers.

**LncRNA in liver cancer**

The analysis of tumor-associated RNA within EVs could provide an opportunity for identification of novel biomarker candidates. While much attention has been given to aberrantly expressed tumor-associated protein-coding mRNAs, genome sequencing studies have identified deregulated tumor-associated expression of several noncoding RNAs such as miRNAs, and lncRNAs. In contrast to the extensive studies on mRNAs and miRNAs, our understanding of the role of lncRNAs in disease remains limited [11]. LncRNAs are genetically encoded RNA molecules that lack protein coding potential and are defined by a size >200 bp [11]. The majority of lncRNAs are transcribed by RNA polymerase II, and then undergo polyadenylation and pre-RNA splicing [12]. LncRNAs have been reported to have many diverse functions involved in regulation of gene expression through epigenetic regulation, chromatin modification, transcription or posttranscriptional processing [13]. lncRNAs have emerged as important regulators of gene expression in many cancers [14]. The emerging relevance to cancer supports the utility of this class of RNA genes as cancer biomarkers. Alterations in expression of several lncRNAs have been recently reported in HCC. Selected examples are listed in Table 1 and are described herein [12, 14–16]. Recent studies have identified several lncRNA, such as TUC339, linc-VLDLR and lincRNA regulator of reprogramming (linc-RoR) that have been detected within HCC-derived EV [2, 4, 17].

**Highly upregulated in liver cancer**

This RNA gene was first identified as a lncRNA that was highly specifically upregulated in HCC [18]. Highly upregulated in liver cancer (HULC) inhibits miR-372 activity in an autoregulatory loop that reduces translational repression of its target gene, protein kinase A catalytic subunit beta (PKAβ), and in turn inducing the phosphorylation of camp response element-binding protein (CREB), a transcriptional factor that regulates HULC expression [19]. HULC is aberrantly expressed in HCC tissues and in the plasma of HBV-positive HCC patients [20]. Overexpression of HULC can be an indicator of lower survival rate [15]. HULC expression is upregulated in HBx-producing cell lines, and upregulation of HULC by HBx suppresses p18 activity and promotes HCC cell proliferation [21]. HULC has been detected with higher frequency in the plasma of HCC patients when compared with healthy controls, and with greater frequency in patients with higher Edmondson histological grades [20]. HULC thus has potential value as a biomarker of HCC [20].

**HOX antisense intergenic RNA**

This lncRNA is significantly overexpressed in HCC tissues and liver cancer cell lines and has also been implicated in many other cancers. HOX antisense intergenic RNA (HOTAIR) induces transcriptional silencing of homebox D cluster (HOXD) genes by
targeting the polycomb repressive complex 2 (PRC2) complex to the HOXD locus [22]. High HOTAIR expression was correlated with poor patient survival and tumor recurrence [23]. HOTAIR levels in HCC tissues are higher when compared with adjacent noncancerous tissue. HOTAIR may also have utility as a prognostic marker for predicting HCC recurrence following liver transplantation [24].

**Metastasis-associated lung adenocarcinoma transcript 1**

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a large IncRNA and is >8000 nucleotides in length [25]. This IncRNA has been found to be involved in tumor metastasis and is implicated in a wide range of cancers [14]. MALAT1 localizes to nuclear speckles and functions in regulation of alternate splicing by altering the levels of phosphorylated to dephosphorylated serine/arginine-rich (SR) proteins [26]. MALAT1 levels are highly upregulated in HCC, with a nearly 6-fold increase in HCC compared with normal liver tissue [27]. MALAT1 overexpression has also been linked to cancer metastasis and tumor recurrence in patients following liver transplantation [27]. Therapeutic treatments that target MALAT1 can decrease cancer cell viability following transplantation and could be of clinical value [11].

**H19 imprinted maternally expressed transcript**

H19 is an imprinted gene that is normally expressed in fetal liver and placenta during embryonic development, but is repressed after birth in most tissues [11]. Overexpression of H19 in adults is indicative of tumor development and growth [14]. High expression of H19 has been shown to be associated with HBV-related HCC [28]. The chromosomal location of this IncRNA is adjacent to the insulin-like growth factor 2 (IGF2) gene, and the biallelic expression of H19 and IGF2 may play a causal role in the epigenetic mechanisms involved in tumorigenesis in HCC [29].

**LncRNA with high expression in HCC**

High levels of LncRNA with high expression in HCC (IncRNA-HEIH) in HBV-related HCC are markedly associated with recurrence, and can function as an independent prognostic marker for survival [11]. IncRNA-HEIH is also associated with cancer recurrence, with high expression predicting a worse prognosis [12]. This IncRNA interacts with the enhancer of zeste homolog 2 (EZH2) and represses the activity of EZH2 target genes p15, p16, p21, and p57, which are all important cyclin-dependent protein kinase inhibitors [30].

**Maternally expressed gene 3**

Maternally expressed gene 3 (MEG3) has been found to be highly expressed in normal tissue but is downregulated in a number of human tumors [11]. The expression of MEG3 is decreased in HCC tumor tissues compared with nonmalignant tissues [31].

### Table 1. LncRNAs associated with hepatocellular carcinoma

| LncRNA ID | Full name / gene description | Chromosomal location | Size (Kb) | Biological function | References |
|-----------|-------------------------------|----------------------|-----------|---------------------|------------|
| HULC      | Highly up-regulated in liver cancer | Chr 6p24.3 | 0.5 | Promotes HCC growth by inhibiting miR-372 | [18–21] |
| HOTAIR   | HOX antisense intergenic RNA | Chr 12q13.13 | 2.3 | Promotes cell proliferation by silencing HOXD genes | [22–24] |
| MALAT1   | Metastasis-associated lung adenocarcinoma transcript 1 | Chr 11q13.1 | 8.7 | Promotes cell invasion by regulating alternate splicing | [11, 25–27] |
| H19      | Imprinted maternally expressed untranslated transcript | Chr 11p15.5 | 2.3 | Promotes HCC growth through involvement with IGF2 | [11, 14, 28, 29] |
| HEIH      | High expression in HCC | Chr 5q35.3 | 1.7 | Promotes HCC growth by interacting with EZH2 and repressing p15, p16, p21, and p57 | [11, 30] |
| MEG3     | Maternally expressed gene 3 | Chr 14q32.3 | 1.8 | Inhibits cell growth by interacting with PRC2 complex | [11, 16, 31, 32] |
| MVIH     | Microvascular invasion in HCC | Chr 5 | | | |
| TUC338   | Transcribed ncRNA encoding uc. 338 | Chr 12q13.13 | 0.59 | Modulates cell growth by inhibiting p151NK4a and activating CDK | [13, 34] |
| Dreh     | Down regulated expression by HBx | Chr 5 | | Inhibits cell growth and metastasis by repressing vimentin | [35] |
| LET      | Low expression in tumor | Chr 15 | | Suppresses metastasis by destabilizing NF90 | [15, 36] |
| HBx-LINE | Fusion of HBx with cellular long interspersed nuclear elements | Chr 8p11.21 | | Promotes HCC growth by activating Wnt/β-catenin signaling pathway | [15, 37] |
| Ftx      | Encoded in the X-inactivation center, DIST regulator | Xq13.2 | | Promotes tumor growth by activating Wnt signaling pathway | [15, 38] |
| ATB      | Activated by TGF-β | Chr 14 | | Promotes metastasis by binding IL-11 | [39] |
| PVT1     | Plasmacytoma variant translocation 1 | 8q24 | | Promotes cell proliferation by binding NOP2 | [40] |
| PCNA-AS1 | Antisense to proliferating cell nuclear antigen | 20p12.3 | | Promotes HCC growth by regulating and stabilizing PCNA | [41] |
| LincRNA-RoR | lncRNA-regulator of reprogramming | Chr 18 | 22.8 | Promotes tumor cell survival during hypoxic stress | [17] |
| TUC339   | Transcribed ncRNA encoding uc. 339 | Chr 12 | 1.2 | Modulates tumor cell growth and adhesion | [4] |
Furthermore, enforced expression of MEG3 in HCC cells notably inhibited cell growth and increased apoptosis [31]. It has been suggested that the Delta-like 1 homolog (DLK1)-MEG3 locus is continually deregulated in HCC [32].

**LncRNA-microvascular invasion in HCC**

Upregulation of microvascular invasion in HCC (MVIH) has been shown to be associated with increased microvascular invasion and metastasis in HCC tissues [33]. Furthermore, high levels of MVIH can serve as an independent predictor of poor recurrence-free survival following hepatectomy in HCC patients [33]. This IncRNA is located in the intron of the ribosomal protein S24 (RPS24) gene and encodes a protein that belongs to the S24E family of ribosomal proteins [11]. MVIH may activate tumor-inducing angiogenesis by inhibiting the secretion of phosphoglycerate kinase 1 (PGK1) [33].

**TUC338**

This lncRNA encompasses a sequence that is highly conserved across species and markedly upregulated in HCC cells compared with nonmalignant cells [34]. TUC338 expression corresponds to disease stage suggesting a potential role during malignant transformation [34]. Targeting TUC338 can be an effective method of modulating HCC growth [13]. TUC338 functions in controlling the G1/S checkpoint of the cell cycle by inhibiting p161NK4a and activating cyclin D1 / cyclin-dependent kinases (CDK).

**LncRNA downregulated expression by HBx**

Downregulated expression by HBx (Dreh) is significantly downregulated in HBV-related HCC, and is associated with poor disease prognosis [35]. This IncRNA targets the intermediate filament vimentin and alters normal cytoskeleton structure, and inhibits HCC growth and metastasis both in vitro and in vivo [35].

**Low expression in tumor**

Low expression in tumor (LET) levels were found to be decreased in tumor samples of HCC patients when compared with normal tissue [36]. Downregulation of LET by histone deacetylation 3 mediated hypoxia-induced HCC metastasis [36]. LET binds to and destabilizes nuclear factor of activated T-cells 90 kDa (NF90), a double-stranded RNA-binding protein that is implicated in tumor growth and metastasis [15].

**LncRNA-Hbx-LINE**

The expression of HBx-LINE, short for fusion of the HBV encoded X protein and human cellular long interspersed nuclear elements, is upregulated in HCC tissues and associated with poor patient prognosis, and thus could potentially serve as a predictor of patient survival [37]. The HBx-LINE1 sequence is transcribed by the HBx promoter, and involves a fusion of HBx with cellular long interspersed nuclear elements (LINEs) [37]. HBx-LINE functions in tumor growth by activating Wnt signaling and inducing nuclear localization of β-Catenin [15]. HBx-LINE levels are upregulated in HCC tissues, and associated with increased colony formation, cell migration and epithelial-mesenchymal transition of tumor cells [37].

**LncRNA-Ftx**

This lncRNA is encoded within the X-inactivation center and has been implicated in HBV-associated HCC [38]. Ftx may function in HCC tumor growth by activating the Wnt signaling pathway [15]. The Ftx transcript encodes miR-545/374a, both of which showed increased expression in tumor tissue compared with noncancerous tissue taken from patients with HBV-related HCC [15]. Gender differences in miR-545/374a expression are recognized with male HCC patients having higher expression than females [15].

**IncRNA activated by TGF-β**

IncRNA activated by TGF-β (IncRNA-ATB) is a mediator of the transforming growth factor (TGF-β) signaling pathway, and is highly expressed in HCC tissues [39]. IncRNA-ATB promotes the invasion-metastasis cascade by binding to Ikerleukin 11 (IL-11) and triggering STAT3 signaling [39]. ATB expression is upregulated in metastatic disease and associated with poor disease prognosis, which could make it a potential HCC biomarker as well as a candidate target for anti-metastatic therapies [39].

**Plasmacytoma variant translocation 1**

Plasmacytoma variant translocation 1 (PVT1) was found to be highly upregulated in HCC tissues and was associated with poor clinical prognosis in patients [40]. PVT1 increases Nucleolar Protein 2 (NOP2) levels by enhancing the stability of NOP2 RNA-binding protein [40]. PVT1 may promote cell proliferation, cell cycling and the acquisition of stem cell-like properties in HCC cells.

**Proliferating cell nuclear antigen antisense lncRNA**

The proliferating cell nuclear antigen antisense lncRNA (PCNA-AS1) transcript is located opposite to the PCNA gene, and may regulate PCNA activity via RNA hybridization [41]. This antisense lncRNA has been implicated in HCC growth and tumorigenesis [41]. PCNA-AS1 is significantly upregulated in HCC compared with paratumoral tissues both in vitro and in vivo. Patients with high levels of PCNA-AS1 were also more inclined to develop multiple tumors.

**IncRNA regulator of reprogramming**

This lncRNA was first identified as an epigenetic regulator involved in pluripotency and lineage commitment, and is significantly upregulated in malignant hepatocytes as well as enriched within EVs derived from tumor cells [42]. Recent studies show that lncRNA-RoR expression is increased during tumor hypoxia [17].

**TUC339**

This is an ultraconserved RNA that is highly enriched within EVs released from HCC-derived tumor cells and has been implicated in modulating tumor cell growth and adhesion [4].

The emerging data on lncRNA involved in HCC indicates the presence of several tumor-associated lncRNA, some of which have been functionally linked to processes involved in tumor growth. Given the large repertoire of transcribed lncRNA within the genome, many more lncRNA associated with HCC are likely to emerge. Once associations with the presence, behavior or outcomes of HCC are ascertained, these will represent attractive candidates for further evaluation as biomarkers of disease.

**Technologies for detection of circulating lncRNA biomarkers**

Accurate and sensitive detection of candidate lncRNA biomarkers in the circulation is a prerequisite for their use as biomarkers of...
RNA Isolation

Detection and Quantification of lncRNA

RNA Isolation

Total RNA

Isolation of extracellular vesicles

Extracellular vesicle RNA

Figure 2. Overview of approach to analysis of circulating IncRNA as biomarkers of disease. A major determinant of success will be the availability of assays that have adequate sensitivity to detect small amounts of IncRNA in circulation, and knowledge of disease-specific IncRNA. (A colour version of this figure is available online at: http://bfg.oxfordjournals.org)

Table 2. Platforms for detection of IncRNA

| Technology                  | RNA quantity | Basic principle                                                                 | Advantages                                                                                                   | Disadvantages                                                                                     |
|-----------------------------|--------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| qPCR                        | Nanograms    | Amplifies a specific region of interest. Uses fluorescence signals to quantify PCR product. | Well-established and cost-effective technique. Less amount of starting material needed. Results are reproducible. | Requires reference genes and standard curves. Not effective at detecting small amounts of RNA.          |
| dPCR                        | Nanograms    | Partitions sample into multiple smaller reactions, performs amplification and detects ratio of positive to negative reactions. | Improved precision and accuracy. No need to depend on standard curves of endogenous controls. High sensitivity. | Expensive and lengthy procedure.                                                                      |
| Microarrays                 | 30 ng–5 μg   | Probes are hybridized to fluorescent-labeled RNA. Probes are scanned and processed to detect RNA expression. | Able to simultaneously detect several genes. Can be customized.                                                | Low sensitivity. Expression levels are lower for IncRNA.                                         |
| NanoString nCounter Gene Expression Assay | Single cell  | Probes are hybridized to target RNA. Machine digitally counts color-coded probe pairs to quantify gene expression. | Can detect multiple genes in a single reaction. High sensitivity and specificity.                             | Expensive technique.                                                                             |
| NGS                         | 1–5 μg       | Template is created. Adaptors bind to gene of interest. Gene is amplified and sequenced. | High-throughput sequencing. Reduced cost and lessened sequencing time.                                         | Shorter average read lengths. Data analysis is time-consuming and complex.                         |
disease or as markers to monitor disease progression, treatment effect or prognosis (Figure 2). Starting from blood or plasma, EV can be isolated using sequential ultracentrifugation or size-exclusion chromatography and EV RNA isolated [5]. Alternatively, total RNA can be isolated from blood samples. The latter will include both EV-associated RNA as well as free or protein-bound RNA. Several platforms are available for the detection of circulating RNA and include quantitative real-time polymerase chain reaction (qRT-PCR), droplet digital PCR (ddPCR), microarrays, nanostring and next-generation sequencing (NGS) [43] [Table 2]. However, the sensitivity of detection of the RNA transcripts of interest is the most important determinant. While tumor cells may release large amounts of EV, the absolute amount of a tumor-specific RNA in circulation will be extremely small.

Microarrays are commonly used for RNA detection and are based on nucleic acid hybridization between target molecules and their complementary probes [44]. The signal intensities at their corresponding locations are used as a measure of relative RNA abundance [45]. Because microarrays consist of short length recognition sequences, each melting temperature (Tm) is different, and this may negatively affect the specificity and sensitivity [46]. With the use of microarrays, the expression levels of IncRNA are also generally lower than protein coding genes [45]. An advantage of using microarrays is that it allows for the simultaneous detection of a large number of RNA genes, and arrays can be customized [46].

Quantitative PCR (qPCR) is a well-established tool for quantifying gene expression that relies on an increase in fluorescence signal that is proportional to the polymerase reaction product or amplicon [47]. Quantitative information is obtained from the cycle threshold (Ct), which is defined as the PCR cycle at which the fluorescent signal of the reported dye crosses an arbitrary threshold [48]. The Ct value is inversely related to the amount of amplicon in the reaction; hence, a lower Ct value indicates greater gene expression [48]. Typically, Ct values for specific genes are referenced to well-known housekeeping genes such as GAPDH. However, this could be problematic because the housekeeping genes vary in expression between cell populations. The use of qPCR is limited because it requires an adequate standard curve to be generated for each sequence of interest [47]. Furthermore, this technique is not well-suited for detecting small amounts of RNA [43]. A limitation for the use of qRT-PCR for detection of EV RNA is the lack of information about housekeeping genes to enable quantitation across samples.

The NanoString nCounter Gene Expression Assay is a novel technology to measure RNA expression [46]. The assay is based on the direct detection of mRNA molecules of interest using target-specific, color-coded barcode probe pairs containing 35–50 base target-specific sequences. [49]. Digital analysis is then performed by quantitatively barcodes [50]. This technology does not require amplification or reverse transcription, and because the counts are measured digitally, it is possible to detect small levels of RNA with high accuracy [46], and several hundred unique transcripts could be analyzed in a given reaction [50]. A comparison of the NanoString nCounter with microarrays and TaqMan PCR reported that the nCounter system is more sensitive than microarrays and similar in sensitivity to real-time PCR [49]. The sensitivity to detect EV RNA has not yet been determined.

Digital PCR (dPCR) offers an alternative and more direct approach for detecting gene expression; dPCR involves the partitioning of a sample into multiple separate reactions, such that some reactions contain no nucleic acid template and others contain one or more template copies [51]. The partitioned solutions undergo thermal cycling and end-point PCR. In ddPCR, droplets are generated and individual droplets analyzed using a fluorescence detector and used to determine the target concentration [43]. Unlike real-time PCR, dPCR allows for absolute quantification of a nucleic acid without the need for standard curves or endogenous controls. DPCR also offers improved precision and accuracy, thereby enabling smaller fold change differences to be detected [51]. DdPCR is ideal for the quantification of EV RNA samples, and is advantageous in studies where the target RNA concentration is low [47]. We have reported the use of dPCR for the detection of EV RNA.

NGS offers a powerful tool for detecting RNA molecules in biological samples. NGS initially requires the generation of a small RNA library in which the 5’ and 3’ RNA adaptors are ligated to either end of the noncoding RNA. The 3’ adaptors then bind to other small RNAs that carry the corresponding 3’ hydroxyl group. This is followed successively by reverse transcription and PCR amplification [46]. NGS is based on the concept of sequencing by synthesis, each DNA fragment to be sequenced is bound to an array, and DNA polymerase adds labeled nucleotides sequentially [52]. NGS is often referred to as ‘massively parallel sequencing’ because it is capable of sequencing a large number of different DNA sequences in a single reaction [53]. A limitation of NGS is that it provides shorter average read lengths (30–400 bp) than conventional Sanger-based methods (400 bp–1 kb) [54], and these shorter reads may not align uniquely to the reference gene. The greatest advantage with NGS is the capability of producing a high volume of sequence data sets in the range of megabases to gigabases [54]. Reduced cost and shorter sequencing times are making NGS a more viable option for biomarker research [55]. However, the utility for detection of EV IncRNA remains to be established.

**Opportunities for IncRNA as disease biomarkers**

An increasing number of IncRNA are being reported to be aberrantly expressed in human cancers. Characterization of these tumor-associated IncRNA offers the possibility of providing new insights into disease pathogenesis. IncRNA can be detected in EV released by tumor cells and can be detected in the circulation. However, the low expression of these in circulation and assays for clinical use will require highly sensitive detection technologies such as dPCR or next-generation sequencing. In addition to establishing tumor specificity, successful application of emerging knowledge of IncRNA will require the development of sensitive and reliable assays and a systematic demonstration of their clinical utility as biomarkers for disease diagnosis, prognosis, prediction of recurrence and therapeutic response. Such data are becoming available for several IncRNAs, for example HOTAIR and MALAT1 in predicting tumor recurrence following liver transplantation for HCC [16]. While the integrity and functional role of such IncRNAs and their presence within EV have yet to be established, the specificity of release from tumor cells within EV offers promise for their use as disease biomarkers.

---

**Key Points**

- Alterations in the expression of several IncRNAs such as HOTAIR and MALAT1 have been reported in many cancers.
- Aberrant expression of IncRNA that is specific to certain tumors, such as HULC in hepatocellular cancer, support a role for these in disease pathogenesis.
• The differences in lncRNA present in tumor cells and in extracellular vesicles derived from these cells supports the existence of mechanisms that selectively enrich lncRNA within extracellular vesicles.

• New quantitative methods for RNA gene analysis such as digital PCR are enabling sensitive measurements of RNA within extracellular vesicles that will facilitate their adoption as cancer biomarkers.

Funding

Supported by Grants DK 069370 and UH3-TR000884 from the National Institutes of Health.

References

1. Povero D, Eguchi A, Li H, et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PloS One 2014;9(12):e113651.

2. Takahashi K, Yan IK, Wood J, et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res 2014;12(10):1377–87.

3. Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genom Proteom Bioinform 2015;13(1):17–24.

4. Kogure T, Yan IK, Lin WL, et al. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer 2013;4(7–8):261–72.

5. Patel T. Extracellular vesicle noncoding RNA: new players in the diagnosis and pathogenesis of cholangiocarcinoma. Hepatology 2014;60(3):782–4.

6. Qi J, Wang J, Katayama H, et al. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013;60(2):135–42.

7. Tampaki M, Doumba PP, Deutsch M, et al. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015;7(14):1834–42.

8. Bupathi M, Kaseb A, Meric-Bernstam F, et al. Hepatocellular carcinoma: where there is unmet need. Mol Oncol 2015;9(8):1501–9.

9. Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol 2011;7(1):16–24.

10. Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015;7(12):1632–51.

11. Yu FJ, Zheng JJ, Dong PH, et al. Long non-coding RNAs and hepatocellular carcinoma. Mol Clin Oncol 2015;3(1):13–17.

12. Takahashi K, Yan I, Haga H, et al. Long noncoding RNA in liver diseases. Hepatology 2014;60(2):744–53.

13. Bracconi C, Patel T. Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets 2012;12(9):1073–80.

14. Yang X, Xie X, Xiao YF, et al. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett 2015;360(2):119–24.

15. Moyo B, Nicholson SA, Arbuthnot PB. The role of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Virus Res. 2015;21:7208–17.

16. He Y, Meng XM, Huang C, et al. Long noncoding RNAs: Novel insights into hepatocellular carcinoma. Cancer Lett 2014;344(1):20–7.

17. Takahashi K, Yan IK, Haga H, et al. Modulation of hypoxia-signal pathways by extracellular linc-RoR. J Cell Sci 2014;127(Pt 7):1585–94.

18. Panzitt K, Tschemernatsch MM, Guelly C, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007;132(1):330–42.

19. Wang J, Liu X, Wu H, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010;38(16):5366–83.

20. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int 2013;2013:136106.

21. Du Y, Kong G, You X, et al. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 2012;287(31):26302–11.

22. Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007;129(7):1311–23.

23. Ishibashi M, Kogo R, Shibata K, et al. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. Oncol Rep 2013;29(3):946–50.

24. Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011;18(5):1243–50.

25. Lin R, Maeda S, Liu C, et al. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007;26(6):851–8.

26. Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained non-coding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010;39(6):925–38.

27. Lai MC, Yang Z, Zhou L, et al. Long non-coding RNA MALAT1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012;29(3):1810–6.

28. Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62(14):3939–44.

29. Kim KS, Lee YI. Biallelic expression of the H19 and IGFL2 genes in hepatocellular carcinoma. Cancer Lett 1997;119(2):143–8.

30. Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011;54(5):1679–89.

31. Bracconi C, Kogure T, Valeri N, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011;30(47):4750–6.

32. Anwar SL, Krech T, Hasemeier B, et al. Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PloS One 2012;7(11):e49462.

33. Yuan SX, Yang F, Yang Y, et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology 2012;56(6):2231–41.

34. Bracconi C, Valeri N, Kogure T, et al. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA 2011;108(2):786–91.
35. Huang JF, Guo YJ, Zhao CX, et al. Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology 2013:57(5):1882–92.

36. Yang F, Huo XS, Yuan SX, et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 2013:49(6):1083–96.

37. Lau CC, Sun T, Ching AK, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 2014:25(3):335–49.

38. Zhao Q, Li T, Ji Q, et al. The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. PloS One 2014:9(10):e109782.

39. Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014:25(5):666–81.

40. Wang F, Yuan JH, Wang SB, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology 2014:60(4):1278–90.

41. Yuan SX, Tao QF, Wang J, et al. Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. Cancer Lett 2014:349(1):87–94.

42. Takahashi K, Yan IK, Kogure T, et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio 2014:4:458–67.

43. Takahashi K, Yan IK, Kim C, et al. Analysis of extracellular RNA by digital PCR. Front Oncol 2014:4:129.

44. Zhao B, Ding S, Li W, et al. Hybridization kinetics analysis of an oligonucleotide microarray for microRNA detection. Acta Biochim Biophys Sinica 2011:43(7):551–5.

45. Lund SH, Gudbjartsson DF, Rafnar T, et al. A method for detecting long non-coding RNAs with tiled RNA expression microarrays. PloS One 2014:9(6):e98999.

46. Moreno-Moya JM, Vilella F, Simon C. MicroRNA: key gene expression regulators. Fertil Steril 2014:101(6):1516–23.

47. Dodd DW, Gagnon KT, Corey DR. Digital quantitation of potential therapeutic target RNAs. Nucleic Acid Ther 2013:23(3):188–94.

48. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008:3(6):1101–8.

49. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008:26(3):317–25.

50. Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol 2011:Chapter 25:Unit25B 10.

51. Wang P, Jing F, Li G, et al. Absolute quantification of lung cancer related microRNA by droplet digital PCR. Biosen Bioelectron 2015:74:836–42.

52. Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med 2015:7(1):80.

53. Zhang J, Chiodini R, Badr A, et al. The impact of next-generation sequencing on genomics. J Genet Genom 2011:38(3):95–109.

54. Rizzo JM, Buck MJ. Key principles and clinical applications of ‘next-generation’ DNA sequencing. Cancer Prev Res 2012:5(7):887–900.

55. Lopez JP, Diel A, Cruceanu C, et al. Biomarker discovery: quantification of miRNAs and other small non-coding RNAs using next generation sequencing. BMC Med Genom 2015:8:35.